Iovance awards Noah Berkowitz 180K-share stock grant

The options and RSUs are subject to continued employment and staged vesting; PSU vesting is tied to regulatory milestones disclosed on Form 8-K.

Rhea-AI Filing Summary

Iovance Biotherapeutics, Inc. (IOVA) reported direct equity awards to Chief Medical Officer Noah Berkowitz on September 30, 2026: options covering 135,000 shares, 180,000 restricted stock units, and 135,000 performance stock units. The options have a $14.82 exercise price and expire September 30, 2036. Provided he remains employed with Iovance on the applicable dates, one-third of the options and RSUs vest on the grant’s one-year anniversary; the remainder vest in eight equal quarterly installments over the next two years, beginning with the first quarter after that anniversary. Each RSU represents a contingent right to one common share. Up to 135,000 shares underlying the PSUs may be earned subject to regulatory milestones; earned PSUs vest when Iovance publicly discloses receipt of certain milestones on Form 8-K. Each PSU converts into one common share.

Insider Trade Summary

Grant/Award: 450,000 shares

Grant/Award 3 txns

Insider Berkowitz Noah

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy) F1	135,000	$0.00	$0.00
Grant/Award	Restricted Stock Units F2, F1	180,000	$0.00	$0.00
Grant/Award	Performance Stock Units F3, F4, F5	135,000	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 135,000 contracts (Direct); Restricted Stock Units — 180,000 contracts (Direct); Performance Stock Units — 135,000 contracts (Direct)

Footnotes (5)

1. F1. Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
3. F3. Each performance stock unit ("PSU") converts into one share of the Issuer's common stock.
4. F4. Up to 135,000 shares of the Issuer's common stock underlying the PSUs may be earned subject to achievement of certain regulatory milestones.
5. F5. Such earned PSUs shall vest on the date that the Issuer publicly discloses on a Form 8-K with the U.S. Securities and Exchange Commission its receipt of certain regulatory milestones.

Key Figures

Options: 135,000 shares Option exercise price: $14.82 per share Option expiration: September 30, 2036 +3 more

6 metrics

Options 135,000 shares Awarded September 30, 2026

Option exercise price $14.82 per share Options awarded September 30, 2026

Option expiration September 30, 2036 Options awarded September 30, 2026

Restricted stock units 180,000 units Awarded September 30, 2026; each RSU represents a contingent right to receive one common share

Performance stock units 135,000 units Awarded September 30, 2026; up to 135,000 underlying shares may be earned subject to regulatory milestones

Vesting schedule One-third; eight equal quarterly installments Options and RSUs, subject to continued employment; remaining awards vest over the next two years beginning with the first quarter after the one-year anniversary

Key Terms

Restricted stock units, Performance stock unit, Regulatory milestones

3 terms

Restricted stock units financial

"the restricted stock units ("RSUs") and options"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Performance stock unit financial

"Each performance stock unit ("PSU") converts into one share"

A performance stock unit is a type of reward companies give to employees, usually managers, that depends on how well the company performs over time. If the company hits specific goals, the employee earns shares of stock, like earning a prize for reaching certain levels in a game. It motivates employees to work hard because their rewards are tied to the company's success.

Regulatory milestones regulatory

"subject to achievement of certain regulatory milestones"

Regulatory milestones are the key official steps a company must reach with government agencies—such as filings, approvals, clearances or formal reviews—before a product or business activity can move forward. For investors they matter because hitting or missing these milestones can change a company’s ability to sell products, unlock revenue, reduce legal and development risk, or trigger payments, much like a traffic light or checkpoint that determines whether a project can continue on schedule.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did IOVA Chief Medical Officer Noah Berkowitz receive?

On September 30, 2026, Noah Berkowitz received options covering 135,000 shares, 180,000 restricted stock units, and 135,000 performance stock units. The options have a $14.82 exercise price and expire September 30, 2036.

How do Noah Berkowitz's IOVA options and RSUs vest?

Provided he remains employed with Iovance on the applicable dates, one-third of the options and RSUs vest on the grant’s one-year anniversary. The remaining awards vest in eight equal quarterly installments over the next two years, beginning with the first quarter after that anniversary.

What must happen for IOVA performance stock units to vest?

Up to 135,000 shares underlying Noah Berkowitz’s performance stock units may be earned subject to achievement of certain regulatory milestones. Earned units vest on the date Iovance publicly discloses on Form 8-K its receipt of certain regulatory milestones; each unit converts into one common share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 05:01 PM Accepted by SEC EDGAR 10/02/2026 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berkowitz Noah

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

300 ROUSE BLVD.

(Street)

PHILADELPHIA PENNSYLVANIA 19112

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$14.82	09/30/2026		A		135,000		(1)	09/30/2036	Common stock	135,000	$0.00	135,000	D
Restricted Stock Units	(2)	09/30/2026		A		180,000		(1)	(1)	Common stock	180,000	$0.00	180,000	D
Performance Stock Units	(3)	09/30/2026		A		135,000(4)		(5)	(5)	Common stock	135,000	$0.00	135,000	D

Explanation of Responses:

1. Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

3. Each performance stock unit ("PSU") converts into one share of the Issuer's common stock.

4. Up to 135,000 shares of the Issuer's common stock underlying the PSUs may be earned subject to achievement of certain regulatory milestones.

5. Such earned PSUs shall vest on the date that the Issuer publicly discloses on a Form 8-K with the U.S. Securities and Exchange Commission its receipt of certain regulatory milestones.

	/s/ Noah Berkowitz	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)